retatrutide approval timeline Will the FDA approve retatrutide? Odds & Predictions LLY's Retatrutide Nears 2027 Filing

[34] showed that treatment with the GLP-1 RAs exenatide and liraglutide reduced both systolic and diastolic BP by 1 to 5 mm Hg in patients with T2D, compared with some other anti-diabetic drugs, including insulin, glimepiride, and placebo

Fixingeverything

Diana Girnita, a double board-certified rheumatologist with a PhD in immunology and over 20 years of experience

When considering what to eat on Mounjaro or other GLP-1 therapies, focus should shift toward smaller, nutrient-dense portions that prioritise lean proteins and high-fibre vegetables

For example, patients losing more than 10% of body weight over several months may demonstrate higher gallstone incidence

Possible direct effects on skin-supporting cells remain an emerging research question, while the same medications may simultaneously improve inflammatory and metabolic processes within the skin